Webinars

Learn valuable perspectives by watching presentations from industry panelists.

Clinical Outcome Assessments in Early-stage Alzheimer’s Disease Clinical Trials

Clinical Outcome Assessments in Early-stage Alzheimer’s Disease Clinical Trials

Studies of investigational drugs targeting the dementia stage of Alzheimer’s disease (AD) have used a co-primary approach to assess cognitive and functional (or global) measures. This approach ensured both a clinically meaningful effect by a demonstration of benefit on the functional measure and that the observed functional benefit was accompanied by an effect on the core symptoms of the disease as measured by the cognitive assessment.

September 10, 2021
Clinical Trials of Schizophrenia: Optimizing Patient Reported Outcomes and Performance Outcome Assessments

Clinical Trials of Schizophrenia: Optimizing Patient Reported Outcomes and Performance Outcome Assessments

The majority of clinical outcome assessments (COAs) in schizophrenia trials are clinician reported outcome (ClinRO) assessments such as the PANSS and various forms of CGI and functional instruments which use information from clinical interviews with the patient and perhaps a caregiver. These COAs provide critical insights into clinical status, making use of the expertise and insight of psychiatrists and other healthcare professionals.

June 10, 2021
Early Detection of Alzheimer’s Disease: Deficits in Learning Appear Before Memory Impairment

Early Detection of Alzheimer’s Disease: Deficits in Learning Appear Before Memory Impairment

There is now conjecture that disease-modifying therapies for AD may be most effective in the preclinical stages of the illness and therefore drug development programs are focusing on this stage of the disease. The large effects of amyloid observed on learning paradigms over short time periods suggests they could be a useful cognitive challenge model for early phase studies seeking to understand the effects of drugs designed to improve cognition in AD.

March 31, 2021
Using Cognitive Assessment to Improve Decision Making in Oncology Clinical Trials

Using Cognitive Assessment to Improve Decision Making in Oncology Clinical Trials

Advances in treatments are substantially increasing survival rates in people with cancer. While indices of overall survival and progression-free survival are the most widely accepted clinical endpoints for determining the efficacy of new therapies in oncology, there is growing interest in patient-centered clinical outcome assessments (COAs) to determine the potential benefits and safety of new and existing treatments as well as their effects on level of overall function.

March 10, 2021
Digital Technologies for Assessing Patient Functioning in Multiple Sclerosis Clinical Trials

Digital Technologies for Assessing Patient Functioning in Multiple Sclerosis Clinical Trials

Substantial progress has been made in the development of disease modifying therapeutics for Multiple Sclerosis (MS) in recent years. The array of next-generation compounds for this complicated disease have made great strides in increasing the time between relapse and delaying disease progression.

December 1, 2020
Improving Signal Detection in Rare Disease Clinical Trials

Improving Signal Detection in Rare Disease Clinical Trials

High-quality data are critical when seeking to measure treatment outcomes, but this is especially challenging in rare disease trials where the stakes are high with complex assessments and a limited number of eligible participants. In this webinar, Dr. Pam Ventola will describe customized rater training approaches that meet sponsors’ needs but also are flexible and efficient so to be feasible for sites.

November 11, 2020
A Better Way to Measure Cognitive Safety & Tolerability

A Better Way to Measure Cognitive Safety & Tolerability

Learn how to leverage integrated digital cognitive assessments and patient reports for advanced insights, streamlined delivery and lower burden. Watch the webinar from ERT and Cogstate to learn the value of assessing cognitive safety and tolerability throughout the drug development process, key considerations for selecting and optimizing computerized cognitive assessments, and more.

July 30, 2020
Remote Administration Considerations for Conventional and Computerized Clinical Outcome Assessments

Remote Administration Considerations for Conventional and Computerized Clinical Outcome Assessments

As the COVID-19 pandemic spread, research teams worldwide quickly adapted study plans to safely continue research whenever possible. While some observational studies were put on hold entirely, other therapeutic trials were continued with many or all study activities occurring remotely.

June 23, 2020
Covid-19: Considerations for Clinical Outcome Assessments in Clinical Trials

Covid-19: Considerations for Clinical Outcome Assessments in Clinical Trials

Cogstate senior scientists came together (digitally) from three continents to discuss clinical outcome assessments in the COVID-19 era. We invite you to watch the video of their roundtable discussion.

June 1, 2020
Clinical Outcome Assessments in Preclinical Alzheimer’s Disease: Considerations for Global Clinical Trials

Clinical Outcome Assessments in Preclinical Alzheimer’s Disease: Considerations for Global Clinical Trials

Clinical trials designed to study interventions at the preclinical AD stage are using fit-for-purpose clinical outcome assessments that have high validity and reliability for the detection of cognitive change at this early stage of the illness. This webinar outlines the application of several preclinical stage instruments for use in industry clinical trials.

November 28, 2019
Selecting Cognitive & Behavioral Endpoint Measures for Trials in Rare Epilepsy and MPS Disorders

Selecting Cognitive & Behavioral Endpoint Measures for Trials in Rare Epilepsy and MPS Disorders

Clinical trials in patients with rare disease present considerable challenges, as patients with these conditions are typically heterogeneous and many are quite impaired. In this webinar, Dr. Pamela Ventola describes important factors to consider when selecting cognitive and behavioral endpoints for these trials and shares strengths and application considerations for several key scales.

November 28, 2019
Using Cognition to Guide Decisions on the Safety and Tolerability of Drugs in Clinical Development

Using Cognition to Guide Decisions on the Safety and Tolerability of Drugs in Clinical Development

In clinical trials, changes in performance on cognitive tests can provide a sensitive index of the impact of a drug on the central nervous system. This webinar details how the detection of decline in specific aspects of cognition, or in cognition in general, is important for making decisions about target engagement, maximum tolerated dose and pharmacodynamic profile.

July 25, 2019

How can we help you optimize the measurement of brain health?

Please fill out the form to get in touch